G1 Therapeutics, Inc. (GTHX)
| Market Cap | 959.61M |
| Revenue (ttm) | 45.29M |
| Net Income (ttm) | -99.25M |
| Shares Out | 37.88M |
| EPS (ttm) | -2.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $23.39 |
| Previous Close | $23.07 |
| Change ($) | 0.32 |
| Change (%) | 1.39% |
| Day's Open | 22.95 |
| Day's Range | 22.48 - 23.50 |
| Day's Volume | 2,273,899 |
| 52-Week Range | 8.80 - 37.07 |
- Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutio...
Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 28.72% year over year to ($0.67), which be...
- G1's COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March -
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a ...
G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bon...
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy -
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1's Chief Executive Officer Jack ...
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors' and officers' possi...
G1 Therapeutics has a PDUFA date coming up on February 15, 2021 for its first therapy, trilaciclib in SCLC. G1's stock has moved hugely upward over the last few months as investors begin to an...
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Baile...
- Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) -
Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader (SERD) rintodestrant for ER+, HER2- breast cancer Company also presents updated mono...
GTHX stock is depressed but I don't see any reason. PDUFA of Feb. 15, 2021, is a major catalyst.
RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer J...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data f...
RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Baile...
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2020 Results - Earnings Call Transcript
RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and confere...
RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that four presentations highlighting th...
- Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors
RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that two presentations highlightin...
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that the company will participate ...
Oncology Stocks Area Trading Materially Lower The Last 2 Months
Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.
- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration - Priority Review for trilaciclib is based on positive data from three randomized clinical trials showin...
G1 Therapeutics' (GTHX) CEO Mark Velleca on Q2 2020 Results - Earnings Call Transcript
- Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC) - Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch - Partnership for trila...
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark V...
RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that it will host a webcast and con...
- G1 to receive $20 million upfront payment, sales royalties and potential milestone payments of up to $290 million for commercialization of lerociclib in the U.S., Europe, Japan
- Partnership leverages Boehringer Ingelheim’s oncology expertise to lead trilaciclib SCLC launch sales engagements - G1 to retain full development and commercialization rights and book reven...
G1 Therapeutics Has Multiple Roadmaps To A Multi-Billion Dollar Market Cap
- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments - Genor to lead clinical development, regulatory submissions and commercializati...
As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.
G1 Therapeutics (GTHX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Non-dilutive capital to support commercialization and additional development of trilaciclib - Non-dilutive capital to support commercialization and additional development of trilaciclib
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2020 Results - Earnings Call Transcript
- Jack Bailey appointed to Board of Directors- Soma Gupta joins as Chief Commercial Officer- Company reports inducement grant under Nasdaq Listing Rule 5635 (c)(4)
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q4 2019 Results - Earnings Call Transcript
RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark V...
SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX ) announced today a c...
RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today reported additional data from...
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Vel...
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2019 Results - Earnings Call Transcript
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and confe...
Some investors think the market's been too hard on these drugmakers.
About GTHX
G1 Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is i... [Read more...]
| Industry Biotechnology | IPO Date May 17, 2017 |
| CEO Mark Velleca | Employees 122 |
| Stock Exchange NASDAQ | Ticker Symbol GTHX |
Analyst Forecasts
According to 8 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is 59.00, which is an increase of 152.24% from the latest price.